CDK12: an emerging therapeutic target for cancerGoldie Y.L. Lui, Christopher J. Kemp, Carla Grandori|Journal of Clinical Pathology|2018Cited by 134
BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancerGoldie Y.L. Lui, Carla Grandori, Reid Shaw et al.|EBioMedicine|2020Cited by 38
Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell CarcinomaShogo Shigeta, Christopher J. Kemp, Goldie Y.L. Lui et al.|Molecular Cancer Therapeutics|2021Cited by 30
Abstract 534: Functional drug screening of organoids from ovarian cancer patients demonstrates clinical and genomic concordance and identifies novel therapeutic vulnerabilitiesGoldie Y.L. Lui, Carla Grandori, Isabella N. Stork et al.|Cancer Research|2021Cited by 4
Data from Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell CarcinomaShogo Shigeta, Christopher J. Kemp, Goldie Y.L. Lui et al.|Unknown|2023Cited by 0